Should Canadian patients look forward to aducanumab for Alzheimer disease?
Jennifer A Watt1, Roger Marple2, Brenda Hemmelgarn2
1Knowledge Translation Program (Watt, Straus), Li Ka Shing Knowledge Institute, St. Michael's Hospital; Division of Geriatric Medicine, Department of Medicine (Watt, Straus), University of Toronto, Toronto, Ont.; Patient partner (Marple), Medicine Hat, Alta.; Faculty of Medicine and Dentistry (Hemmelgarn), University of Alberta, Edmonton, Alta.; Institute of Health Policy, Management and Evaluation (Straus), Dalla Lana School of Public Health, University of Toronto, Toronto, Ont. jennifer.watt@mail.utoronto.ca.
Abstract
No abstract available in PubMed .
More Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
305
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
305
01:26Alzheimer's Disease: Overview
764
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
764